On Monday, Following U.S. Stocks were among the “Top Gainers”: Sigma Designs, Inc. (NASDAQ:SIGM), Opexa Therapeutics, Inc. (NASDAQ:OPXA), Globalstar Inc. (NYSEMKT:GSAT), NeoPhotonics Corporation (NYSE:NPTN)
Sigma Designs, Inc. (NASDAQ:SIGM), with shares inclined 7.96%, closed at $7.87, hitting new 52-week high of $7.93.
Opexa Therapeutics, Inc. (NASDAQ:OPXA), with shares jumped 7.64%, settled at $0.69.
Globalstar Inc. (NYSEMKT:GSAT), with shares climbed 7.14%, and closed at $3.30.
NeoPhotonics Corporation (NYSE:NPTN), surged 6.88%, and closed at $5.59.
Latest NEWS regarding these Stocks are depicted underneath:
Sigma Designs, Inc. (NASDAQ:SIGM)
The administration of Sigma Designs, Inc. (SIGM), a leading provider of system-on-chip (SoC) solutions for Smart TV, Internet of Things for Smart home, media connectivity and set-top-boxes (STBs), presented at the 27th Annual ROTH Conference on March 9, 2015.
Sigma Designs, Inc. (NASDAQ: SIGM) is a world leader in enabling smart home convergence. The corporation designs and builds the essential semiconductor technologies that serve as the foundation for the world’s leading IPTV set-top boxes, Smart TV, connected media players, Internet of Things (IoT) for smart home devices and residential gateways and whole home media connectivity.
Opexa Therapeutics, Inc. (NASDAQ:OPXA)
Formerly on March 9, Opexa Therapeutics, Inc. (OPXA), declared that it has amended its option and license contract with Merck Serono (a division of Merck, Darmstadt, Germany) and will receive a $3 million payment. The payment provides support for the ongoing Phase 2b clinical study of Tcelna® (imilecleucel-T), Opexa’s personalized immunotherapy in development for patients with Secondary Progressive MS (SPMS), in addition to the preparation and planning of potential Phase 3 studies.
Opexa and Merck Serono reached the original option and license contract for the development and commercialization of Tcelnain MS in February of 2013, at which time Opexa received a $5 million upfront payment. Following the original contract, Merck Serono has an option to attain an exclusive, worldwide (not including Japan) license of Opexa’s Tcelna program for the treatment of MS. The option may be exercised by Merck Serono preceding to or upon completion of Opexa’s ongoing Phase 2b Abili-T trial of Tcelna in patients with SPMS. Top-line data from the Abili-T trial is predictable in the second half of 2016. Tcelna has received Fast Track Designation from the U.S. Food and Drug Administration for SPMS.
Opexa Therapeutics, Inc., a biopharmaceutical corporation, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology.
Globalstar Inc. (NYSEMKT:GSAT)
Earlier on March 2, Globalstar Inc. (GSAT), declared its financial and operating results for the fourth quarter and year ended December 31, 2014.
FOURTH QUARTER FINANCIAL REVIEW:
Proceed for the fourth quarter of 2014 was $22.1 million contrast to $21.0 million for the fourth quarter of 2013, an raise of 5%, which was driven by raises in both service proceed and subscriber equipment proceed.
Net revenue was $92.0 million for the fourth quarter of 2014 as contrast to a net loss of $234.8 million for the fourth quarter of 2013. This fluctuation results primarily from the influence of non-cash gains in the fourth quarter of 2014 due to a decrease in the value of the Corporation’s derivative liabilities. This decrease in value was driven primarily by the decrease in the Corporation’s stock price during the fourth quarter of 2014. Conversely, the influence of non-cash losses during the fourth quarter of 2013 was due to an raise in the value of the Corporation’s net derivative liabilities during the fourth quarter of 2013, which was driven primarily by the raise in the Corporation’s stock price during the fourth quarter of 2013. The fourth quarter of 2014 was also favorably influenced by lower interest expense of $9.4 million as contrast to $28.0 million in the 2013 quarter driven primarily by conversions of our 5% Notes during 2013 that did not recur in 2014. Depreciation expense declined 19% to $19.8 million in the fourth quarter of 2014 as contrast to $24.5 million in the 2013 quarter due to the depreciable lives of certain first-generation assets coming to an end in 2014.
Adjusted EBITDA for the three-month periods ended December 31, 2014 and 2013 was $3.8 million and $3.9 million, respectively. This decrease in Adjusted EBITDA was due to a $1.5 million raise in proceed offset by a $1.6 million raise in expenses (both not including EBITDA adjustments). The raise in expenses in the fourth quarter of 2014 was driven primarily by the higher cost of subscriber equipment sales, which grew in line with equipment proceed. Additionally, a rebate program introduced during 2014 influenced proceed generated from Duplex equipment sales and raised subscriber attainment costs.
Globalstar provides mobile satellite voice and data services. Globalstar offers these services to commercial customers and recreational consumers in more than 120 countries around the world. The Corporation’s products comprise mobile and fixed satellite telephones, simplex and duplex satellite data modems, flexible airtime service packages and the SPOT family of mobile satellite consumer products counting the SPOT Satellite GPS Messenger.
NeoPhotonics Corporation (NYSE:NPTN)
Formerly on March 3, NeoPhotonics Corporation (NPTN), declared financial results for its fourth quarter and year ended December 31, 2014. On Monday, March 16, NeoPhotonics filed SEC form 10-K, Annual Report.
NeoPhotonics Corporation designs and manufactures photonic integrated circuits-based optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
